We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Yescarta

News List

NHS England reaches deal with Gilead on CAR-T therapy Yescarta pharmaceutical-technology
October 09, 2018
National Health Service (NHS) England has reached an agreement with Gilead Sciences to provide the pharmaceutical company’s chimeric antigen receptor T-cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) for adults with large cell lymphoma.
Gilead's CAR-T cell therapy Yescarta gains EU clearance; meets first resistance from NICE firstwordpharma
August 29, 2018
Gilead Sciences' Kite unit announced that the European Commission approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
Gilead could make a move for Galapagos within weeks pharmaphorum
December 18, 2017
The share price of Belgium-Dutch biotech Galapagos is rising thanks to renewed speculation that Gilead may be poised to acquire it.
FDA approves Yescarta to treat adults with B-cell lymphoma europeanpharmaceuticalreview
October 20, 2017
The FDA has approved Yescarta, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma…

Previous page 1 2 Next page